Handelsbanken Fonder AB Buys New Shares in Enliven Therapeutics, Inc. $ELVN
Handelsbanken Fonder AB acquired 17,300 shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN) valued at approximately $878,000 during the second quarter. Institutional investors and hedge funds now collectively own 95.08% of the company's stock, while insider transactions show sales totaling $11.3 million over the past 90 days. Despite a recent earnings miss, analysts maintain a "Moderate Buy" rating with an average price target of $75.00 for ELVN.
Benjamin Hohl Sells 6,018 Shares of Enliven Therapeutics (NASDAQ:ELVN) Stock
Enliven Therapeutics CFO Benjamin Hohl sold 6,018 shares of ELVN stock on August 17th for over $352,000, reducing his direct ownership by 13.07%. This transaction was part of a pre-arranged trading plan, following similar sales in July and June. Despite the insider selling, analyst sentiment remains a "Moderate Buy" with an average price target of $75.00, though the company recently missed EPS expectations.
Enliven (NASDAQ: ELVN) CFO sells 6,018 shares in 10b5-1 plan
Enliven Therapeutics, Inc.'s CFO, Benjamin Hohl, sold a total of 6,018 shares of Common Stock in two open-market transactions on August 17, 2026, under a Rule 10b5-1 trading plan. The sales were executed at weighted average prices around $58-$59 per share. A portion of these securities were restricted stock units (RSUs), contingent on vesting conditions.
Enliven Therapeutics (ELVN) CMO exercises options, sells stock
Enliven Therapeutics' Chief Medical Officer, Helen Louise Collins, exercised options for 5,000 shares at $2.48 per share and subsequently sold all 5,000 shares in the open market for approximately $293,000. These transactions, conducted under a Rule 10b5-1 trading plan adopted in October 2025, involved two tranches of sales at weighted average prices of $58.3717 and $59.3465. Following these transactions, Collins directly holds 111,268 stock options and 25,000 common stock shares.
Barclays Initiates Enliven Therapeutics at Overweight With $78 Price Target
Barclays has initiated coverage on Enliven Therapeutics (NASDAQ: ELVN) with an Overweight rating and a price target of $78. This indicates a positive outlook from the investment bank on the biopharmaceutical company's future performance.
Enliven Therapeutics (NASDAQ:ELVN) Now Covered by Barclays
Barclays has initiated coverage on Enliven Therapeutics (NASDAQ:ELVN) with an "overweight" rating and a $78 price target, suggesting a potential upside of 31.03%. This comes amidst mixed analyst sentiment, with a consensus "Moderate Buy" rating and an average target price of $75. The company recently reported a quarterly loss of $0.49 per share, missing analyst expectations, and has seen significant insider selling while institutional investors have increased their holdings.
ENLIVEN THERAPEUTICS, INC. : WILLIAM BLAIR INITIATES COVERAGE WITH OUTPERFORM RATING
William Blair has initiated coverage of Enliven Therapeutics, Inc. (ELVN.O) with an Outperform rating. The report, sourced from Reuters, indicates a positive outlook from the investment firm for the pharmaceutical company.
261,344 Shares in Enliven Therapeutics, Inc. $ELVN Acquired by TimesSquare Capital Management LLC
TimesSquare Capital Management LLC has acquired 261,344 shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN) for approximately $13.3 million, representing a 0.43% stake in the company. Institutional investors now collectively own 95.08% of ELVN. Despite a recent EPS miss, analyst sentiment remains positive with a "Moderate Buy" rating and an average price target of $72.67.
Enliven Therapeutics, Inc. (NASDAQ:ELVN) Given Consensus Recommendation of "Moderate Buy" by Brokerages
Enliven Therapeutics (NASDAQ:ELVN) has received a "Moderate Buy" consensus rating from brokerages, with an average 12-month price target of $72.67. This comes despite the company reporting a wider-than-expected quarterly loss of $0.49 per share. Recent insider selling, including a director's $9.6 million sale, has also occurred, with insiders collectively selling over $10 million in shares last quarter.
Stifel Maintains Enliven Therapeutics(ELVN.US) With Buy Rating, Maintains Target Price $82
Stifel has reiterated its Buy rating on Enliven Therapeutics (ELVN.US) and maintained its target price at $82. This indicates a continued positive outlook from the firm regarding the company's stock performance and potential.
Tema ETFs LLC Grows Stake in Enliven Therapeutics, Inc. $ELVN
Tema ETFs LLC significantly increased its stake in Enliven Therapeutics (NASDAQ:ELVN) by 41% in the second quarter, now owning 60,694 shares valued at $3.08 million. This comes as institutional investors hold a substantial 95.08% of the company's stock, despite the company missing quarterly earnings estimates. Analysts generally maintain a "Moderate Buy" rating for ELVN, though insiders have recently sold a considerable amount of stock.
Certain Common Stock of Enliven Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 11-AUG-2026.
Certain common stock of Enliven Therapeutics, Inc. (ELVN) are under a 61-day lock-up agreement, preventing executive officers and directors from selling or disposing of shares and related securities. This lock-up period began on June 11, 2026, and will end on August 11, 2026. The restrictions are designed to prevent market volatility post-offering.
Janus Henderson Group PLC Sells 1,660,724 Shares of Enliven Therapeutics, Inc. $ELVN
Janus Henderson Group PLC significantly reduced its stake in Enliven Therapeutics (NASDAQ:ELVN) by selling 1.66 million shares, retaining only 11,000 shares. Despite this, institutional investors still hold about 95.1% of the stock. Insider selling, including substantial sales by directors, also occurred, even as analysts largely maintain a "Moderate Buy" consensus with an average price target of $72.67, despite the company missing its latest quarterly earnings estimates.
Assenagon Asset Management S.A. Makes New Investment in Enliven Therapeutics, Inc. $ELVN
Assenagon Asset Management S.A. has acquired a new stake in Enliven Therapeutics (NASDAQ:ELVN), purchasing 306,574 shares valued at approximately $15.56 million. Other institutional investors have also adjusted their holdings in ELVN, while company insiders have recently sold shares totaling over $10 million. Analysts have set an average "Moderate Buy" rating and a consensus price target of $72.67 for Enliven Therapeutics.
Certain Options of Enliven Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 11-AUG-2026.
Certain options of Enliven Therapeutics, Inc. are under a lock-up agreement that will end on August 11, 2026. This agreement restricts executive officers and directors from selling or otherwise disposing of shares of common stock and related securities for 61 days, starting from June 11, 2026. The restrictions are designed to prevent market instability after a public offering.
LifeSci Capital Maintains Enliven Therapeutics(ELVN.US) With Buy Rating, Maintains Target Price $70
LifeSci Capital has reiterated its Buy rating for Enliven Therapeutics (ELVN.US) and maintained its target price at $70. This indicates a continued positive outlook from the firm regarding the company's stock performance and potential.
LifeSci Capital Maintains Enliven Therapeutics(ELVN.US) With Buy Rating, Raises Target Price to $70
LifeSci Capital has reiterated its Buy rating for Enliven Therapeutics (ELVN.US) and increased its target price to $70. This updated target price indicates a strong positive outlook from the firm regarding the company's future performance.
A Quick Look at Today's Ratings for Enliven Therapeutics(ELVN.US), With a Forecast Between $68 to $82
This article provides a quick look at current analyst ratings for Enliven Therapeutics (ELVN.US), noting a forecast price range of $68 to $82. It summarizes that the company has received 1 Buy rating and 1 Strong Buy rating from analysts.
Enliven Therapeutics director Mika Derynck sells $9.56m shares
Enliven Therapeutics director Mika Derynck sold 158,795 shares of company stock for approximately $9.
Enliven Therapeutics (ELVN) director exercises options, sells 158,795 shares
Enliven Therapeutics director Mika K. Derynck exercised stock options for 158,795 shares on August 4, 2026, at various exercise prices, then sold all 158,795 shares at a weighted average price of $60.2134 per share. These transactions were conducted as part of a Rule 10b5-1 trading plan adopted in April 2025, with all options being fully vested and exercisable. The total gross sale proceeds were approximately $9.56 million, resulting in an approximate pre-tax spread of $7.84 million.
Enliven Therapeutics, Inc. Stock 12‑Month Price Target Raised to $70.9, Implies 19% Upside
Enliven Therapeutics, Inc. (ELVN) has seen its average 12-month price target raised from $65.8 to $70.9 by 10 analysts, suggesting a 19% potential upside from its Aug. 5 closing price. The consensus rating from 11 covering analysts remains a "Buy," with no hold or sell recommendations. Investors can find more detailed analyst data and historical recommendations on TradingView's Forecasts tab and News Flow.
ENLIVEN THERAPEUTICS, INC. : GUGGENHEIM CUTS TARGET PRICE TO $78 FROM $80
Guggenheim has reduced its target price for Enliven Therapeutics, Inc. (ELVN.O) from $80 to $78. This financial adjustment was reported by Reuters. The article itself is a brief news update, with no further details provided regarding the reasons for the target price cut.
FMR LLC and Abigail Johnson disclose 15% Enliven Therapeutics (ELVN) ownership
FMR LLC and Abigail P. Johnson have filed an amended Schedule 13G/A, disclosing a 15.0% beneficial ownership stake in Enliven Therapeutics Inc. (ELVN). This ownership amounts to 10,713,540.41 shares of common stock, with FMR LLC holding sole voting power over 10,704,808 shares and both FMR LLC and Abigail Johnson having sole dispositive power over all reported shares. The filing indicates that this investment is for ordinary course of business purposes and not intended to influence control of the issuer.
ENLIVEN THERAPEUTICS, INC. : JEFFERIES RAISES TARGET PRICE TO $69 FROM $59
Jefferies has increased its target price for Enliven Therapeutics, Inc. (ELVN.O) to $69 from the previous $59. This adjustment indicates a positive outlook from the investment bank on the company's future performance. The article, sourced from Reuters, provides no further details on the rationale behind the price target change.
Guggenheim lowers Enliven Therapeutics stock price target to $78 By Investing.com
Guggenheim has reduced its price target for Enliven Therapeutics (NASDAQ:ELVN) to $78 from $80, while maintaining a Buy rating. This adjustment follows the company's second-quarter 2026 results and an update on ELVN-001, which received FDA Fast Track Designation and is expected to begin Phase 3 trials in the second half of the year. Despite the stock's significant year-to-date surge of 288%, InvestingPro analysis indicates it may be overvalued, though the company holds more cash than debt.
Enliven Therapeutics, Inc. 2Q 2026: Net loss $32.5M, EPS $(0.49) — 10-Q Summary
Enliven Therapeutics, Inc. reported a net loss of $32.5 million for the second quarter of 2026, an increase from $25.3 million in the prior year, with diluted loss per share remaining flat at $(0.49). The company continues to be pre-revenue, focusing on advancing its ELVN-001 pipeline candidate and has discontinued ELVN-002 development. Increased R&D investment and recent funding rounds provide a cash runway for at least 12 months, with facility expansions supporting future growth.
Enliven Therapeutics (NASDAQ: ELVN) details planned stock sales via Jefferies
Enliven Therapeutics (NASDAQ: ELVN) has filed a Form 144 notice detailing proposed sales of common stock through Jefferies LLC. The filing specifies various stock option positions from 2022 to 2025, outlining the number of common shares to be sold. This transparency measure is intended to inform the market about upcoming share dispositions.
95,253 Shares in Enliven Therapeutics, Inc. $ELVN Acquired by DV Trading LLC
DV Trading LLC recently acquired 95,253 shares of Enliven Therapeutics (NASDAQ:ELVN), valued at approximately $3.7 million, making it their 16th largest holding. This acquisition comes as institutional investors collectively own 95.08% of the company, and Enliven Therapeutics reported better-than-expected quarterly earnings. Despite some insider selling, analysts maintain a "Moderate Buy" rating with a consensus price target of $70.50.
Price to book forward of Enliven Therapeutics, Inc. – NASDAQ:ELVN
The article displays the "Price to book forward" for Enliven Therapeutics, Inc. (NASDAQ: ELVN) on TradingView. It indicates that the market is currently closed with no trades, and the value for this financial metric is not provided within the snippet. The article also lists various navigation and product links related to the TradingView platform.
Trading Systems Reacting to (ELVN) Volatility
Enliven Therapeutics Inc. (NASDAQ: ELVN) is exhibiting neutral near-term sentiment amidst mid and long-term strength, characterized by a mid-channel oscillation pattern. AI models have developed distinct trading strategies for ELVN, including position, momentum breakout, and risk hedging, to optimize position sizing and minimize drawdown risk. The analysis also highlights strong support and resistance signals across different time horizons, with a notable 48.9:1 risk-reward short setup targeting 14.1% downside.
Enliven Therapeutics Inc (ELVN) Technical Analysis: Support, Resistance, Indicators & Moving Averages
This article provides a technical analysis of Enliven Therapeutics Inc (ELVN), detailing its stock performance, market capitalization, and various technical indicators. It presents a summary of buy, sell, and neutral signals based on MACD, RSI, KDJ, ATR, CCI, Williams %R, TRIX, StochRSI, and moving averages (MA5 to MA200). The analysis concludes with a "Neutral" signal based on moving averages and other technical indicators.
ELVN|Enliven Therapeutics Inc|Price:53.720|Chg%:+0.985
This article provides an in-depth financial overview of Enliven Therapeutics Inc (ELVN), including its current stock price, market trends, key financial figures, and analyst ratings. It highlights the company's focus on developing small molecule inhibitors for cancer treatment and lists its major shareholders. The article also includes technical indicators and a comparison with peer companies in the biopharmaceutical sector.
Enliven Therapeutics Inc (ELVN) Valuation: PE, PB & Fair Value Analysis
This article provides a valuation analysis for Enliven Therapeutics Inc (ELVN), focusing on P/E, P/B, and P/CF ratios. However, it notes that relevant data for these metrics have not yet been disclosed by the company. The stock closed at $52.750, down 0.38%, with a market cap of $3.14 billion.
Enliven Therapeutics Inc (ELVN) Cash Flow
This article provides a detailed cash flow statement for Enliven Therapeutics Inc (ELVN), presenting quarterly and annual data for operating, investing, and financing activities. It also defines various cash flow terms and offers answers to frequently asked questions regarding ELVN's financial performance. Investors can use this information to assess the company's financial soundness and stability.
ELVN|Enliven Therapeutics Inc|Price:52.950|Chg%:+0.140
This article provides details on Enliven Therapeutics Inc (ELVN), including its current stock price, market cap, and a note that a stock score is unavailable due to insufficient data. It also explains the methodology TradingKey uses to generate various scores such as financial health, company valuation, earnings forecast, price momentum, institutional confidence, and risk management, which are based on numerous indicators and data points.
ELVN|Enliven Therapeutics Inc|Price:52.950|Chg%:+0.140
Enliven Therapeutics Inc. is a clinical-stage biopharmaceutical company focusing on developing small molecule inhibitors for cancer treatment, with two main product candidates, ELVN-001 and ELVN-002, targeting chronic myeloid leukemia and HER2 mutations, respectively. The article provides detailed company information, including its background, financial data, market performance, executive team, and institutional shareholdings. As of Q1 2026, 307 institutions hold shares, with a significant increase in institutional shareholding compared to Q4 2025.
Enliven Therapeutics, Inc. Revenue Breakdown – NASDAQ:ELVN
This page provides financial information for Enliven Therapeutics, Inc. (ELVN) on Nasdaq Stock Market through TradingView. It offers an overview of financials, including statements, statistics, dividends, earnings, and segments, but currently shows no trade data as the market is closed. The content emphasizes data integrity and various tools available on the TradingView platform for financial analysis.
Goldman Sachs Maintains Enliven Therapeutics(ELVN.US) With Buy Rating, Raises Target Price to $67
Goldman Sachs has reaffirmed its Buy rating on Enliven Therapeutics (ELVN.US) and increased its price target to $67. This indicates a positive outlook from the investment bank regarding the company's future stock performance.
Enliven Therapeutics Insider Sold Shares Worth $316,780, According to a Recent SEC Filing
An insider at Enliven Therapeutics recently sold shares valued at $316,780, as detailed in a new SEC filing. The transaction involved a significant sale of company stock by an internal stakeholder. This information is critical for investors monitoring insider activity within the company.
Enliven Therapeutics chief medical officer Collins sells $263k in shares
Helen Louise Collins, Chief Medical Officer at Enliven Therapeutics, sold 5,000 shares of the company’s common stock for approximately $263,373 on July 17, 2026. These sales were based on a Rule 10b5-1 trading plan and occurred while the stock was near its 52-week high, although InvestingPro analysis suggests it is overvalued. Collins also exercised stock options for 5,000 shares on the same day, expanding her direct beneficial ownership to 25,000 shares.
Enliven Therapeutics Insider Sold Shares Worth $263,373, According to a Recent SEC Filing
An insider at Enliven Therapeutics sold shares valued at $263,373, as reported in a recent SEC filing. This transaction was disclosed on July 21, 2026. Enliven Therapeutics is a clinical-stage biopharmaceutical company focused on developing small molecule therapeutics for conditions like chronic myeloid leukemia and HER2-positive cancers.
Enliven Therapeutics (NASDAQ: ELVN) CFO sells 6,018 shares after option exercise
Enliven Therapeutics (NASDAQ: ELVN) CFO Benjamin Hohl reported exercising stock options for 1,072 shares and selling 6,018 common shares on July 17, 2026. These transactions were executed under a pre-arranged Rule 10b5-1 trading plan adopted on March 18, 2026. Following these transactions, Hohl holds 84,966 stock options and 46,054 common shares directly.
Enliven Therapeutics, Inc. (ELVN) CMO exercises options, sells 5,000 shares
Enliven Therapeutics' Chief Medical Officer, Helen Louise Collins, exercised stock options for 5,000 shares at $2.48 each and subsequently sold all 5,000 shares in multiple transactions with weighted average prices ranging from $49.72 to $53.93. These transactions, executed on July 17, 2026, were performed under a Rule 10b5-1 trading plan established in October 2025. After these trades, Collins directly holds 116,268 stock options and 25,000 common shares.
Enliven Therapeutics Insider Sold Shares Worth $316,780, According to a Recent SEC Filing
An insider at Enliven Therapeutics (ELVN) recently sold shares valued at $316,780, as detailed in a new SEC filing. The company, a clinical-stage biopharmaceutical firm, is focused on developing small molecule therapeutics, including ELVN-001 for chronic myeloid leukemia and ELVN-002 for HER2 inhibition. This transaction follows several other insider share sales reported in recent months.
Enterprise value to revenue forward of Enliven Therapeutics, Inc. – NASDAQ:ELVN
The article displays the enterprise value to revenue forward for Enliven Therapeutics, Inc. (NASDAQ:ELVN). It is presented as a financial data point within TradingView's market overview for the company. No specific values are provided in the content itself, indicating this is likely a placeholder or a header for dynamic data.
ELVN Maintained by Goldman Sachs -- Price Target Raised to $67.0
Goldman Sachs has maintained a "Buy" rating for Enliven Therapeutics (ELVN) and raised its price target from $59.00 to $67.00, indicating increased confidence in the company's potential. Despite this optimistic analyst view, the company's GF Score™ is 28/100, suggesting challenges in profitability and growth, and insiders have sold $53.2 million in shares recently. Investors are advised to consider both the positive analyst outlook and financial concerns before making investment decisions.
Enterprise value to EBIT forward of Enliven Therapeutics, Inc. – NASDAQ:ELVN
This page provides financial data for Enliven Therapeutics, Inc. (NASDAQ: ELVN), specifically focusing on its enterprise value to EBIT forward. It is presented on TradingView, a platform offering market data and financial tools. The content includes general company information, stock market details, and links to various TradingView features, though the core financial data regarding the enterprise value to EBIT is implicitly the focus rather than explicitly stated figures.
Price to earnings forward of Enliven Therapeutics, Inc. – BOATS:ELVN
This article provides "Price to earnings forward" data for Enliven Therapeutics, Inc. (ELVN), accessible through the TradingView platform. It highlights the stock's financial overview within the health technology and biotechnology sectors. The content primarily consists of navigation and platform information, with specific financial data indicated as "Period Value Change Change %."
How Enliven Therapeutics Inc. (ELVN) Affects Rotational Strategy Timing
This article analyzes Enliven Therapeutics Inc. (ELVN) and its impact on rotational strategy timing, highlighting strong sentiment across all time horizons. It provides AI-generated trading strategies including position trading, momentum breakout, and risk hedging, along with detailed multi-timeframe signal analysis. The report suggests compelling upside potential for ELVN based on current market conditions and the absence of resistance levels.
Form 144 Enliven Therapeutics For: 17 July By Investing.com
This article from Investing.com reports on a Form 144 filing for Enliven Therapeutics (ELVN) on July 17. The brief piece indicates that ELVN saw a 4.60% increase, providing only the date and the company's stock performance. Additional content focuses on market data for various indices, commodities, and shares.
